Two large-scale randomised phase III studies, CLASSIC (Adjuvant Chemotherapy Trial of Capecitabine Plus Oxaliplatin for Gastric Cancer) and ACTS-GC (Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer), have demonstrated that adjuvant chemotherapy reduces the risk of relapse and improves overall survival (OS) in patients with locally advanced gastric cancer after D2 lymph node dissection (LND) ([@bib13]; [@bib3]). Although the benefit of this approach following D0 or D1 LND has not been documented in randomised clinical trials, adjuvant chemoradiotherapy (ACRT) is considered the standard of treatment for this subpopulation of gastric cancer patients as demonstrated by the results of INT-0116 (ACRT Trial for Gastric Cancer; [@bib11]).

The benefit of ACRT for patients with D2 LND in locally advanced gastric cancer remains controversial. The ARTIST trial, which was the first randomised phase III trial in Asian patients undergoing D2 LND that compared the efficacy of capecitabine plus cisplatin to capecitabine with concurrent radiotherapy, failed to demonstrate that adding ACRT could improve disease-free survival (DFS) and OS ([@bib10]). However, the results for a subgroup of patients with node-positive gastric cancer suggested a significant DFS effect of ACRT ([@bib12]). Therefore, adding ACRT to adjuvant chemotherapy should be considered to improve clinical outcomes for this group of patients.

S-1 is a combination drug that sustains higher plasma concentrations of 5-fluorouracil (5-FU) and reduces its gastrointestinal toxicity ([@bib14]). The drug has yielded high tumour response rates (\>40%) when administered as monotherapy in phase II studies ([@bib8]) and has shown noninferiority to infusional 5-FU or UFT (a combination of tegafur and uracil) in phase III trials for patients with advanced gastric cancer ([@bib18]).

Several studies have proved that intensity-modulated radiotherapy (IMRT) is superior to two- or three-dimensional radiotherapy, as it provides a more conformal and homogeneous dose to the planning target volume and accordingly minimises the risk of toxicity ([@bib17]). The aims of this phase I/II clinical trial were to determine (a) the optimal dose of S-1 when administered in combination with IMRT and (b) the safety and efficacy of this combination as an adjuvant therapy for patients with node-positive gastric cancer who had undergone radical resection and D1/D2 LND.

Materials and methods
=====================

Eligibility
-----------

Patients were eligible for inclusion in the study if they met the followings: (1) no neoadjuvant treatment, (2) radical surgery with D1/D2 LND, (3) pathologically confirmed adenocarcinoma, (4) positive lymph nodes (PLNs) on postoperative pathological examination, (5) World Health Organisation performance status ⩽1 and age ⩽75 years, (6) haemoglobin level ⩾10.0 g l^−1^, leukocyte count ⩾3.5 × 10^9^ l^−1^, neutrophil count ⩾1.5 × 10^9^ l^−1^, platelet count ⩾100 × 10^9^ l^−1^, and normal liver and kidney function.

Antacid and gastric mucosa protectants were administered on a prophylactic basis. Antiemetic and antidiarrhoeal agents were prescribed when needed. Follow-up assessments included clinical examination, biochemical tests, tests for tumour markers, abdominopelvic computed tomography (CT), and chest radiography and/or CT. Patients were followed up once every 3 months for the first 2 years and every 6 months thereafter.

Both the phase I and phase II studies were approved by the ethics committee of our hospital and were registered at clinicaltrials.gov (NCT01291407 and NCT02296658). All patients signed informed consent forms.

Radiotherapy
------------

A total irradiation dose of 45 Gy was delivered in daily 1.8-Gy fractions (5 days a week over 5 weeks). Patients were required to be on an empty stomach for 4 h before the CT simulation and take an oral positive contrast (300 ml) 30 min before the simulation to make the small intestine visible. To decrease variability in distention due to gastric filling, a standard meal (300 ml of ready-to-eat canned porridge) was given to the patients 15 min before CT scanning and before each treatment. Patients were placed in a supine position with thermoplastic immobilisation during IMRT with a 6-MV photon beam.

The delineation of the clinical target volume depended on the extension and location of the primary tumour and the guidelines for the involved lymph node region issued by the Japanese Gastric Cancer Association ([@bib6]) and has been published in our previous study ([Supplementary Information](#sup1){ref-type="supplementary-material"}; [@bib19]). The remnant stomach was not routinely included within the radiation field. Dose constraints for organs at risk have also been reported in our previous study ([@bib19]).

Chemotherapy
------------

S-1 was administered twice daily on radiotherapy days, in a dose-escalation schedule of 30 mg m^−2^ day^−1^ (level I), 40 mg m^−2^ day^−1^ (level II), 50 mg m^−2^ day^−1^ (level III), 60 mg m^−2^ day^−1^ (level IV), 70 mg m^−2^ day^−1^ (level V), and 80 mg m^−2^ day^−1^ (level VI).

A maximum 6 months of adjuvant chemotherapy with platinum fluoropyrimidine-based combination regimens were allowed to be performed before or after ACRT depending on the performance status, medical comorbidities, and toxicity profile of the patient.

Study design and statistical analysis
-------------------------------------

*Phase I*. The goal of phase I was to estimate the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of S-1 when administered concurrently with IMRT and to determine the recommended dose (RD) of S-1 for patients with node-positive gastric cancer. Adverse events were coded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. The administration of S-1 was terminated without dose modification if DLT occurred.

DLT was defined as any of the following: grade 4 leukopenia or neutropenia, grade 3--4 thrombocytopenia or anaemia, and grade 3--4 non-haematological toxicity. If DLT occurred in one of the first three patients, three additional patients would be assigned to receive the same dose level. If none of the first three patients initially receiving a given dose level developed DLT, or if only one of the six patients developed DLT, the dose was to be increased to the next level. If a second patient experienced a DLT at the same level, then the escalation was to be stopped, and the MTD would be defined as the level at which the DLT occurred and was considered as RD.

*Phase II*. The aim of the phase II trial was to determine the safety and efficacy of the RD of S-1 combined with IMRT. The primary end point was the 3-year DFS. The secondary end points were OS and toxicity. The 3-year DFS rate was predicted to be improved from 50 to 70% based on the results of INT-0116, with one-sided *α*=0.05 and 80% power. A total of 43 patients were required. Assuming a dropout rate of 15%, 50 patients were needed for the phase II study.

Locoregional recurrence was defined as relapse at the anastomosis site, gastric remnant, duodenal stump, tumour bed, or regional lymph nodes within the radiation field. Relapse in the lymph nodes outside the radiation field, peritoneal implantation, and metastasis to the liver or any other extra-abdominal site were regarded as distant metastases. DFS was defined as the interval from the date of the surgery to the date of recurrence or death from any cause. Survival curves were calculated with the Kaplan--Meier method by means of the SPSS for Windows program, version 20.0 (IBM SPSS, Armonk, NY, USA).

Results
=======

Patient characteristics
-----------------------

Between May 2010 and August 2015, 73 patients were consecutively recruited (Phase I, *n*=27, from May 2010 to June 2013). The patient characteristics are presented in [Table 1](#tbl1){ref-type="table"}. All patients had metastatic lymph nodes; the median number of PLN was 9 (range, 1--45 nodes); and the median number of lymph nodes resected was 31 (range, 8--79 nodes). All patients received various adjuvant chemotherapy regimens based on oxaliplatin and 5-FU analogues, with a median of 6 cycles (range, 2--10 cycles) before or after ACRT, as follows: oxaliplatin, S-1 (*n*=44, 60.3%); paclitaxel/docetaxel, oxaliplatin, and capecitabine/S-1 (*n*=19, 26.0%); oxaliplatin, capecitabine (*n*=6, 8.2%); and oxaliplatin, 5-FU, leucovorin (*n*=4, 5.5%). The median time from surgery to the start of radiotherapy was 5.2 months (range, 1.5--7 months).

Toxicity and treatment compliance
---------------------------------

*Phase I.* The phase I portion of the study enrolled 27 patients; the toxicities observed in these patients have been summarised in [Table 2](#tbl2){ref-type="table"}. At dose level I, one patient experienced grade-3 anorexia and nausea and finished ACRT with a total irradiation dose of 39.6 Gy. At dose level III, one patient developed grade-3 thrombocytopenia and was given a chemotherapy break of 6 weekdays but completed the whole radiotherapy dose. At level VI, none of the first three patients developed a DLT. Three more patients were treated at this level, but none of them had a DLT. Therefore, level VI (S-1, 80 mg m^−2^ day^−1^, on radiotherapy days) was deemed to be the MTD and RD for the phase II study.

*Phase II.* An additional 46 patients were enrolled in the phase II portion of the trial. Six patients treated with the RD in the phase I portion were also included in the phase II analysis for a total of 52 patients. Of the 52 patients, 8 (15.4%) developed grade 3 or 4 toxicities ([Table 3](#tbl3){ref-type="table"}). The most common grade 3--4 toxicities were leukopenia (6 patients, 11.5%), anorexia (5, 9.6%), and nausea (5, 9.6%). No treatment-related deaths occurred.

Three patients (5.8%, 3 out of 52) stopped ACRT and received total doses of 39.6, 23.4, and 41.4 Gy; they discontinued ACRT because of grade 3 neutropenia with fever, grade-4 nausea and vomiting, and personal reasons, respectively. Of the 52 patients, 13 (25%) discontinued the S-1 treatment protocol. In addition to the reasons for the discontinuation of ACRT mentioned above, 10 other patients did not complete the entire course of S-1 treatment because of the following reasons: thrombocytopenia (maximum grade, 3), 4 patients; vomiting (maximum grade, 3), 3 patients; leukopenia (maximum grade, 3), 2 patients; and gastritis (maximum grade, 3), 1 patient. The mean length of the chemotherapy break in these 13 patients was 6.7 days (range, 3--12 days).

Tumour relapse and patient survival at RD in phases I and II
------------------------------------------------------------

The median follow-up duration was 37.6 months (range, 21.8--55.6 months) in the 52 patients who received the RD in phases I and II. Among them, 21 recurrence events and 15 deaths occurred (one due to bowel obstruction and the others due to gastric cancer). The DFS at 3 years, the primary end point of phase II, was 62.2% (95% confidence interval (CI), 48.5--75.9). The 3-year OS, locoregional recurrence--free survival (LRFS), and distant metastasis--free survival were 70.0% (95% CI, 56.3--83.7), 92.2% (95% CI, 84.9--99.5), and 63.5% (95% CI, 49.8--77.2), respectively.

Five patients developed locoregional recurrence. Distant metastasis occurred in 20 patients (38.5%, 20 out of 52). The most common distant metastasis was peritoneal implantation, which occurred in 11 patients (21.2%, 11 out of 52). The median time to recurrence was 17.5 months (range, 3.8--42.0 months). The median time from recurrence to death was 7.0 months (range, 1.5--28.7 months).

Discussion
==========

The results of the present study suggest that ACRT with oral S-1 and 45 Gy IMRT had acceptable safety and efficacy in patients with locally advanced node-positive gastric cancer after radical gastrectomy and D1/D2 LND. The RD of oral S-1 was determined to be 80 mg m^−2^ day^−1^ on radiotherapy days. The 3-year DFS in patients who underwent S-1 chemotherapy at a dose of 80 mg m^−2^ day^−1^ was 62.2%, which did not meet the primary end point of our phase II study.

In China, more and more surgeons have begun performing D2 LND because this is the most widely accepted surgical procedure in Asian and European countries ([@bib4]). In our previous retrospective study of 297 patients with advanced gastric cancer who underwent radical surgery alone, in our specialised cancer hospital between 2002 and 2004, the median number of lymph nodes resected was 18 (range, 4--68 nodes), and the 5-year locoregional recurrence rate was 27.6% ([@bib20]). In the present study, the median number of lymph nodes resected was higher, at 31 nodes (range, 8--79 nodes). A large observational study of a US population-based database found that, in patients undergoing radical gastrectomy for gastric cancer, the survival rate significantly improved with an increase in the number of lymph nodes examined, even when as many as 40 lymph nodes were resected ([@bib16]). Thus, theoretically, the greater number of lymph nodes resected in our study may have provided better locoregional control and possibly a survival advantage. However, this number is still much smaller than those reported by studies from Japan and Korea, in which high-quality D2 LND was performed with a median of \>40 lymph nodes examined ([@bib3]; [@bib7]; [@bib10]). Furthermore, the benefit of ACRT for patients with locally advanced gastric cancer who undergo D2 LND remains controversial. In the ARTIST trial, the locoregional recurrence rate in the adjuvant chemotherapy alone group was already relatively low (13% at 5 years) even without ACRT. However, in the ARTIST trial, only 40% of patients had advanced gastric cancer (stages III and IV (M0), AJCC Sixth edition). On the basis of this, we can estimate that the locoregional recurrence rate might be higher than 15% in patients with stage III or IV (M0) gastric cancer, despite D2 LND, especially in patients outside Japan and Korea or those treated in low-volume general hospitals without much surgical experience in standard D2 LND. Therefore, it is still necessary to investigate the effect of ACRT on locoregional control in high-risk patients with advanced gastric cancer.

[@bib5] analysed the patterns of regional recurrence after D2 LND in patients with pathological N3 stage gastric cancer, according to AJCC Seventh edition (the median number of PLNs was 13, which amounted to 28% of the median number of all lymph nodes examined) and found that nodal recurrence was most commonly detected in lymph nodes at stations 16b, 16a, 12, 14, 13, and 9. Regardless of the location of the primary tumour, lymph nodes at stations 16a and 16b were the most common recurrence sites. These results suggest that, in patients with many PLNs (for example, those with N3 disease), tumour recurrence commonly occurs in lymph nodes located outside the D2 LND field. Thus more prospective studies are required to determine the optimal radiation target volume in such patients and to minimise radiation-related toxicities. The ARTIST-II trial that aims to determine the abovementioned targets in this specific subgroup of high-risk node-positive gastric cancer patients is ongoing, and we look forward to their results.

According to the National Comprehensive Cancer Network guidelines, 5-FU or capecitabine is recommended to be used concurrently with radiotherapy after R0 resection and D0/D1 LND for locally advanced gastric cancer. In East Asia, both capecitabine and S-1 have been approved as combination treatments or monotherapies for advanced gastric cancer and have replaced 5-FU ([@bib3]). Our previous study determined that the MTD and RD of capecitabine was 800 mg m^−2^ twice daily when administered concurrently with IMRT for gastric cancer after surgery ([@bib19]), which is similar to the dose used in the radiotherapy phase of the ACRT group in the ARTIST trial. S-1 has been widely used in China as the ACTS-GC and other studies have reported promising results of adjuvant treatment with S-1 in Asian patients with advanced gastric cancer ([@bib13]; [@bib9]). The RD of 80 mg m^−2^ day^−1^ of S-1 from the present study is now being administered in a randomised phase II trial of neoadjuvant chemotherapy compared with S-1--based chemoradiotherapy in patients with locally advanced gastric cancer in our hospital (NCT02301481). From the preliminary results, the compliance with preoperative chemoradiotherapy was 93.3% for S-1 and 96.7% for radiation ([@bib21]). However, ([@bib1], [@bib2]) have confirmed that the tolerated dose of S-1 is lower in white patients than in Japanese patients. It is most likely because the efficacy of CYP2A6 enzyme is higher in white patients than in Asian patients, which would cause the former to convert tegafur to fluorouracil relatively rapidly, thus achieving a higher area under the curve of fluorouracil than that observed in Asian patients. Therefore, S-1 is not routinely used in the West.

In the present phase II study, the 3-year DFS and OS were 62.2% and 70%, respectively, which did not meet the primary end point of our study (3-year DFS, 70%). The main reasons for this were probably the large number of PLNs found and the relatively low number of total lymph nodes resected during gastrectomy. The median number of PLNs was as high as 11.5 in our phase II study, and 80.8% of our patients had pathological stage III or IV (M0) cancer, according to the AJCC classification (Sixth edition). Second, D2 LND was not performed in all patients in this study. Despite the above, our results are still comparable to those of the ACRT treatment arm in previous clinical trials in which patients underwent D2 LND ([Table 4](#tbl4){ref-type="table"}). A Korean phase III study applying the INT-0116 protocol to patients with stage III or IV (M0) gastric cancer undergoing D2 LND showed that ACRT could provide an LRFS benefit and might subsequently improve DFS but not OS ([@bib7]). The 5-year DFS and OS in the ACRT group were 60.9% and 65.2%, respectively, in the intent-to-treat analyses. However, the patients in the phase II portion of our study had more PLNs than those in this Korean study (median, 11.5 *vs* 8). Recently, another Korean phase II trial evaluating adjuvant S-1/cisplatin chemotherapy with concurrent S-1/radiotherapy in gastric cancer patients after D2 LND (63.1% of patients had stage III or IV (M0) disease, with a median number of PLNs of 5.5) reported 3-year DFS and OS rates of 65.2% and 76.1%, which are similar to our results ([@bib15]).

In this study, the most common grade 3/4 haematological and gastrointestinal toxicities were leukopenia (11.5%) and nausea (9.6%), which were relatively less frequent than those in the aforementioned studies ([@bib7]; [@bib10]; [@bib12]; [@bib15]). The exclusion of the remnant stomach from the radiation field and the application of IMRT may lead to a relatively lower rate of severe haematological (leukopenia/neutropenia) and gastrointestinal (nausea/vomiting) toxicities. The two Korean studies, which irradiated the remnant stomach and used the AP-PA conventional radiation technique, reported leukopenia/neutropenia in 17.4--19.6% of patients and nausea/vomiting in 17.4--28.2% of patients ([@bib7]; [@bib15]). Although the ARTIST trial did not routinely include the remnant stomach in the radiation field, it also reported that 48.4% and 12.3% of patients developed grade 3/4 neutropenia and nausea, respectively. This may be attributable to the use of AP-PA, which is inferior to IMRT and associated with a greater risk of toxicity. Compared with infusional 5-FU, S-1 has similar efficacy and lower gastrointestinal toxicity in patients with advanced gastric cancer due to the active agent oteracil (which reduces the gastrointestinal toxicity of 5-FU) ([@bib2]). Given these reasons, the present study showed acceptable safety and comparable compliance with the treatment course, in which concurrent S-1 was totally completed as planned in 75% of patients (39 out of 52). The radiotherapy course was completed as planned in 94.2% of patients (49 out of 52).

The limitations of this study should also be considered. This is a single-institution study, and its sample size is not large enough to draw a definite conclusion on the survival benefit of ACRT with S-1 treatment for node-positive gastric cancer. Owing to the poor patient recruitment for this study, we did not limit the regimens or cycles of adjuvant chemotherapy administered before or after ACRT. Thus patients received differing adjuvant chemotherapy regimens depending on their oncologist's preference, which may have impacted the results. In addition, the patients were recruited postoperatively, thus generating a bias of selected subgroup of all patients undergoing surgery.

In conclusion, we consider that ACRT with 80 mg m^−2^ day^−1^ oral S-1 twice daily combined with IMRT at a dose of at least 45 Gy in 25 fractions was safe and efficacious. The use of advanced techniques such as IMRT, an appropriate irradiation field, and low-toxicity single-agent chemotherapy regimens such as S-1 is highly recommended. A randomised phase III study in our hospital comparing adjuvant chemotherapy with S-1--based ACRT for node-positive locally advanced gastric cancer after D2 LND is ongoing (NCT02648841), and its results are eagerly awaited.
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###### 
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###### Patient characteristics

                                      **Total (*****n*****=73)**   **Patients given RD (*****n*****=52)**       
  ---------------------------------- ---------------------------- ---------------------------------------- ---- ------
  Age (years), median (range)                53 (29--73)                        53 (29--73)                     
  Men                                             56                                76.7                    38   73.1
  Tumour size (cm), median (range)           4.5 (2--18)                       4.0 (2--11.5)                    
  Location of primary tumour                                                                                       
   Upper 1/3 of stomach                           11                                15.1                    6    11.5
   Middle 1/3 of stomach                          10                                13.7                    8    15.4
   Lower 1/3 of stomach                           39                                53.4                    27   51.9
   ⩾2 sites involved                              13                                17.8                    11   21.2
  Positive LNs, median (range)                9 (1--45)                         11.5 (1--45)                    
  LNs resected, median (range)                31 (8--79)                        34 (14--79)                     
  LN ratio, median (range)                0.32 (0.05--0.90)                  0.30 (0.05--0.90)                  
  Extent of dissection                                                                                             
   D1                                             20                                27.4                    10   19.2
   D2                                             53                                72.6                    42   80.8
  Lauren type                                                                                                      
   Intestinal type                                12                                16.4                    8    15.4
   Diffuse type                                   27                                37.0                    20   38.5
   Mixed type                                     20                                27.4                    14   26.9
   Undetermined                                   14                                19.2                    10   19.2
  Tumour differentiation                                                                                           
   Good                                           1                                 1.4                     1    1.9
   Moderate                                       9                                 12.4                    7    13.4
   Poor                                           63                                86.2                    44   84.7
  Lymphatic/vascular invasion                                                                                      
   Present                                        40                                54.8                    30   57.7
   Absent                                         33                                45.2                    22   42.3
  Perineural invasion                                                                                              
   Present                                        35                                47.9                    32   61.5
   Absent                                         38                                52.1                    20   38.5
  Stage (AJCC Seventh)                                                                                             
   IIa                                            2                                 2.7                     0     0
   IIb                                            6                                 8.2                     3    5.8
   IIIa                                           15                                20.6                    10   19.2
   IIIb                                           35                                47.9                    25   48.1
   IIIc                                           15                                20.6                    14   26.9
  Stage (AJCC Sixth)                                                                                               
   Ib                                             2                                 2.7                     0     0
   II                                             17                                23.3                    10   19.2
   IIIa                                           31                                42.5                    22   42.3
   IIIb                                           7                                 9.6                     6    11.5
   IV                                             16                                21.9                    14   26.9

Abbreviations: AJCC=American Joint Committee on Cancer; LN=lymph node; RD=recommended dose.

###### Dose-limiting toxicities in the phase I study (*N*=27)

  **Level**   **S-1 (mg m**^**−2**^** day**^**−1**^)   ***N***   **Patients with DLT**      **DLT (G3)**    **Radiotherapy dose when DLT occurred (Gy)**
  ----------- ---------------------------------------- --------- ----------------------- ------------------ ----------------------------------------------
  I           30                                       6         1                        Nausea, anorexia  39.6
  II          40                                       3         0                              ---         ---
  III         50                                       6         1                        Thrombocytopenia  45
  IV          60                                       3         0                              ---         ---
  V           70                                       3         0                              ---         ---
  VI          80                                       6         0                              ---         ---

Abbreviation: DLT=dose-limiting toxicity.

###### Overall toxicities at the recommended dose in phases I and II of the study (*N*=52)

  **Toxicity**       **Grades 1--2 (*****N*****, %)**   **Grades 3--4 (*****N*****, %)**
  ------------------ ---------------------------------- ----------------------------------
  Nausea             33 (63.5)                          5 (9.6)
  Vomiting           12 (23.1)                          3 (5.7)
  Anorexia           30 (57.7)                          5 (9.6)
  Oesophagitis       10 (19.2)                          2 (3.8)
  Diarrhoea          2 (3.8)                            0
  Abdominal pain     2 (3.8)                            0
  Stomatitis         13 (25.0)                          1 (1.9)
  Fatigue            29 (55.8)                          1 (1.9)
  Weight loss        6 (11.5)                           0
  HFS                4 (7.7)                            0
  Leukopenia         37 (71.1)                          6 (11.5)
  Neutropenia        25 (48.1)                          2 (3.8)
  Anaemia            11 (21.2)                          0
  Thrombocytopenia   27 (51.9)                          0
  ALT/AST            1 (1.9)                            0

Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; HFS=hand foot syndrome.

###### Results in the adjuvant chemoradiotherapy treatment arms of selected studies on patients with gastric cancer undergoing surgery and D2 lymph node dissection

  **Author (year)**    **Median no. of PLNs**[a](#t4-fn2){ref-type="fn"}**/percentage of patients with stage III or IV (M0)**[a](#t4-fn2){ref-type="fn"}    **Regimen/technique**           **End point**
  ------------------- ----------------------------------------------------------------------------------------------------------------------------------- -------------------------- ----------------------------
  [@bib15]                                                                          5.5/63                                                                     S-1+45 Gy/AP-PA        3-year DFS 65.2%, OS 76.1%
  [@bib7]                                                                            8/100                                                                      FL+45 Gy/AP-PA        5-year DFS 60.9%, OS 65.2%
  [@bib22]                                                                          NM/71.2                                                                     FL+45 Gy/IMRT         5-year DFS 45.2%, OS 48.4%
  ARTIST (2012)                                                                     3/42.1                                                                 Capecitabine+45 Gy/AP-PA       3-year DFS 78.2%,

Abbreviations: AP-PA=anterior--posterior parallel opposing fields; ARTIST=Adjuvant Chemoradiotherapy in Stomach Tumours; DFS=disease-free survival; FL=5-fluorouracil and leucovorin; IMRT=intensity-modulated radiotherapy; NM=not mentioned; OS=overall survival; PLNs=positive lymph nodes.

Among patients treated with ACRT.
